Sanofi India · NSE: SANOFI · BSE: 500674
Q1 FY25 results · Apr–Jun 2024
Sanofi India reported revenue from operations of ₹463.50 crore (down 34.4% from Q1 FY24) and net profit of ₹103.20 crore (down 16.0% from Q1 FY24) for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 463.50 | 706.10 | −34.4% | 732.40 | −36.7% |
| Other income | 4.80 | 15.70 | −69.4% | 6.50 | −26.2% |
| Total income | 468.30 | 721.80 | −35.1% | 738.90 | −36.6% |
| Profit before tax | 92.10 | 183.40 | −49.8% | 188.40 | −51.1% |
| Net profit for the period | 103.20 | 122.90 | −16.0% | 136.60 | −24.5% |
| EPS, basic (₹) | 44.81 | 53.37 | −16.0% | 59.31 | −24.4% |
| Net margin (%) | 22.3 | 17.4 | 18.7 |
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 463.50 | 706.10 | −34.4% | 732.40 | −36.7% |
| Other income | 4.80 | 15.70 | −69.4% | 6.50 | −26.2% |
| Total income | 468.30 | 721.80 | −35.1% | 738.90 | −36.6% |
| Profit before tax | 92.10 | 183.40 | −49.8% | 188.40 | −51.1% |
| Net profit for the period | 103.40 | 122.90 | −15.9% | 136.60 | −24.3% |
| EPS, basic (₹) | 44.90 | 53.37 | −15.9% | 59.31 | −24.3% |
| Net margin (%) | 22.3 | 17.4 | 18.7 |
Consolidated
- Filed with BSE
- 29 Jul 2024, 16:14 IST
- Board meeting
- 26 Jul 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 29 Jul 2024, 16:14 IST
- Board meeting
- 26 Jul 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE